HHV-4 EBNA-2 Inhibitors
Chemical inhibitors of HHV-4 EBNA-2 function by disrupting various cellular signaling pathways that the protein utilizes for gene regulation and other cellular activities. Ro 20-1724 acts as a PDE4 inhibitor, increasing intracellular cAMP levels and thus hindering cAMP-dependent signaling pathways that are essential for HHV-4 EBNA-2's activation of certain genes. Similarly, Gö6976 impedes the activities of Protein Kinase C, a key player in the signaling cascades that HHV-4 EBNA-2 might employ for gene transcription initiation. LY294002 targets the PI3K/Akt pathway by inhibiting PI3K, a kinase that sits upstream of many signaling routes, including those used by HHV-4 EBNA-2. PD98059 focuses on inhibiting MEK, which in turn blocks the MAPK/ERK pathway, another potential route for HHV-4 EBNA-2 to affect gene regulation and cellular proliferation. SB203580 specifically inhibits p38 MAPK, which could interfere with HHV-4 EBNA-2's ability to modulate gene expression through stress response pathways.
The inhibition of HHV-4 EBNA-2 continues with SP600125, which obstructs the activities of JNK, potentially disturbing the AP-1 pathway utilized by HHV-4 EBNA-2 for the regulation of gene expression. The proteasome inhibitor MG132 impedes the degradation of IκB, resulting in NF-κB pathway inhibition, which is another signaling route that HHV-4 EBNA-2 may exploit for the activation of gene expression. SN50 similarly inhibits HHV-4 EBNA-2 by preventing the nuclear translocation of NF-κB, thereby disrupting its transcriptional activation capabilities. YC-1 targets soluble guanylyl cyclase, reducing cGMP levels and affecting signaling pathways that are pivotal for HHV-4 EBNA-2's activation of cellular processes. ICG-001 directly inhibits the Wnt/β-catenin/Tcf signaling pathway, and Triptolide suppresses the activity of both NF-κB and NFAT, both essential pathways for HHV-4 EBNA-2 function. Lastly, Apicidin, as a histone deacetylase inhibitor, can change the chromatin structure and gene expression, altering the expression of genes crucial for HHV-4 EBNA-2's functionality.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ro 20-1724 | 29925-17-5 | sc-200709 sc-200709A sc-200709B | 100 mg 1 g 5 g | $87.00 $426.00 $1574.00 | 17 | |
Ro 20-1724 inhibits phosphodiesterase 4 (PDE4), which leads to an increase in intracellular cAMP levels, thereby inhibiting the cAMP-dependent signaling pathways that HHV-4 EBNA-2 may rely on for the activation of certain genes. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö6976 is a potent inhibitor of Protein Kinase C (PKC). PKC is involved in signaling pathways that HHV-4 EBNA-2 might utilize for the initiation of gene transcription, thus its inhibition can impair HHV-4 EBNA-2 mediated transcriptional activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, a kinase upstream of many signaling pathways including Akt. Since HHV-4 EBNA-2 may utilize PI3K/Akt pathway for its functions, LY294002 can inhibit this pathway, thus inhibiting HHV-4 EBNA-2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which blocks the MAPK/ERK pathway, a pathway that could be crucial for HHV-4 EBNA-2's role in gene regulation and cellular growth, thereby inhibiting the functional activities of HHV-4 EBNA-2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which may interfere with HHV-4 EBNA-2's ability to modulate gene expression through stress response pathways, resulting in functional inhibition of HHV-4 EBNA-2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which could be involved in the AP-1 pathway that HHV-4 EBNA-2 may use to regulate gene expression, leading to its functional inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of IκB, thereby inhibiting the NF-κB pathway which HHV-4 EBNA-2 may use for the activation of viral and cellular gene expression, leading to functional inhibition of HHV-4 EBNA-2. | ||||||
YC-1 | 170632-47-0 | sc-202856 sc-202856A sc-202856B sc-202856C | 1 mg 5 mg 10 mg 50 mg | $33.00 $124.00 $218.00 $947.00 | 9 | |
YC-1 inhibits soluble guanylyl cyclase, thereby reducing cGMP levels which can influence signaling pathways that HHV-4 EBNA-2 might exploit for the activation of certain cellular processes, resulting in functional inhibition of HHV-4 EBNA-2. | ||||||
Erastin | 571203-78-6 | sc-205677 sc-205677A | 5 mg 50 mg | $372.00 $1614.00 | 1 | |
ICG-001 specifically inhibits the Wnt/β-catenin/Tcf signaling pathway, which can be important for HHV-4 EBNA-2 mediated transcriptional activation, leading to the functional inhibition of HHV-4 EBNA-2. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide is known to inhibit the activity of NF-κB and NFAT (nuclear factor of activated T-cells), both of which are pathways that may be exploited by HHV-4 EBNA-2 for its functional activity, thus inhibiting HHV-4 EBNA-2. | ||||||